Stockwatch: New antibiotics: easy to say; hard to do
This article was originally published in Scrip
Most of the contemporary challenges for the western world are easy to identify, but difficult to resolve. These include the pensions time-bomb, the obesity epidemic, the patent cliff, the European sovereign debt crisis and the lack of new antibiotics. While the European sovereign debt crisis lurched into a significantly worse position this week, two other announcements proposed remedies to two of these challenges.
You may also be interested in...
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?